Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Pharmacogenetic characterization of indacaterol, a novel beta 2-adrenoceptor agonist.

Sayers I, Hawley J, Stewart CE, Billington CK, Henry A, Leighton-Davies JR, Charlton SJ, Hall IP.

Br J Pharmacol. 2009 Sep;158(1):277-86. doi: 10.1111/j.1476-5381.2009.00224.x. Epub 2009 Apr 30.

2.

Miniaturized receptor binding assays: complications arising from ligand depletion.

Carter CM, Leighton-Davies JR, Charlton SJ.

J Biomol Screen. 2007 Mar;12(2):255-66. Epub 2007 Jan 26.

PMID:
17259589
3.

In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.

Battram C, Charlton SJ, Cuenoud B, Dowling MR, Fairhurst RA, Farr D, Fozard JR, Leighton-Davies JR, Lewis CA, McEvoy L, Turner RJ, Trifilieff A.

J Pharmacol Exp Ther. 2006 May;317(2):762-70. Epub 2006 Jan 24.

PMID:
16434564
4.

ATP priming of macrophage-derived chemokine responses in CHO cells expressing the CCR4 receptor.

Rosethorne EM, Leighton-Davies JR, Beer D, Charlton SJ.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):64-70. Epub 2004 May 27.

PMID:
15167983

Supplemental Content

Loading ...
Support Center